[Based on Japanese GAAP]
Operating Results
Overview of Operating Results
-
Net sales
35,626 million yen
YOY 1.1%
-
Operating profit
2,740 million yen
YOY 3.5%
-
Ordinary profit
2,862 million yen
YOY 8.5%
-
Profit attributable to owners of parent
2,006 million yen
YOY (9.6)%
-
Earnings per share
70.63 yen
YOY (10.0)%
During the current interim consolidated period, the Japanese economy showed a moderate recovery trend, supported by improved employment and income conditions. However, the outlook remained uncertain due to factors such as the prolonged geopolitical risks and rising prices associated with a weaker yen and higher energy costs, etc. The Group’s core Pharmaceutical Business continues to face a challenging business environment, affected by ongoing policies to curb medical expenses, including annual NHI drug price revisions. Against this backdrop, Group businesses performed steadily, driven by the Pharmaceutical Business and the Animal Health Business. As a result, net sales increased by 373 million yen from the same period last year to 35,626 million yen (up 1.1%).
Looking at profit, despite a deteriorating cost of sales ratio and higher research and development expenses, operating profit was 2,740 million yen (up 3.5%), and ordinary profit was 2,862 million yen (up 8.5%), due to cost reductions in other expenses such as transportation and storage costs. On the other hand, due to factors such as an increase in income taxes compared to the same period last year, profit attributable to owners of parent was 2,006 million yen (down 9.6% year on year).
Segment
Net sales
(Millions of yen)
| Segment name | 1Q | 2Q | 3Q | Full year |
|---|---|---|---|---|
| Pharmaceutical business | 14,484 | 29,615 | ||
| Animal health business | 1,952 | 4,125 | ||
| Overseas businesses | 908 | 1,798 | ||
| Other businesses | 38 | 87 |
(i) Pharmaceutical business
The Pharmaceutical Business, which focuses on three areas, internal medicine, obstetrics and gynecology, and urology, increased sales year on year, despite the impact of annual NHI drug price revisions. By product, sales of dysmenorrhea agent DroEthi fell to 3,854 million yen (down 6.2%) in the obstetrics and gynecology field, while sales of uterine fibroids and endometriosis agent RELUMINA rose 2.6% year on year to 5,838 million yen. Meanwhile, thyroid hormone formulation THYRADIN, a mainstay product in the internal medicine field, grew steadily, reaching sales of 4,554 million yen (up 5.7%), partly due to the impact of a positive revision in the NHI drug price, while the poorly absorbable rifamycin antimicrobial agent RIFXIMA also performed well, reaching sales of 4,163 million yen (up 7.3%). In the urology field, the LH-RH derivative microcapsule sustained release agent leuprorelin recorded sales of 2,222 million yen (up 16.5% year on year).
As a result, segment net sales amounted to 29,615 million yen (up 1.2%), with a segment profit of 3,297 million yen (up 5.7%).
(ii) Animal Health Business
In the Animal Health Business, which offers veterinary pharmaceuticals and feed additives, net sales were 4,125 million yen (up 9.6% year on year), mainly from feed additives. However, segment profit fell 2.2% to 276 million yen due to rising procurement costs for feed additives caused by the weak yen and related factors.
(iii) Overseas Business
Ha Tay Pharmaceutical Joint Stock Company, a Vietnam-based pharmaceutical company, reported net sales of 1,798 million yen (down 15.7% year on year) and segment profit of 53 million yen (down 59.6% year on year), partly due to difficulty in procurement of active pharmaceutical ingredients from the Middle East for the company’s main products.
(iv) Other Businesses
Other businesses, which engage in activities such as clinical testing services and medical devices, recorded net sales of 87 million yen (down 12.0% year on year) and a segment loss of 2 million yen (compared to a loss of 15 million yen a year earlier).
Financial Position
Overview of Financial Position Summary
-
Total assets
111,882 million yen
Change from end of previous fiscal year (0.4)%
-
Net assets
80,225 million yen
Change from end of previous fiscal year 4.4%
-
Equity ratio
65.6 %
Change from end of previous fiscal year 3.0point
Overview of Financial Position
(Assets)
Total assets at the end of the current interim consolidated period amounted to 111,882 million yen, a decrease of 497 million yen from the end of the previous consolidated fiscal year. This was mainly due to decreases in cash and deposits, and other current assets.
(Liabilities)
Total liabilities at the end of the current interim consolidated period amounted to 31,656 million yen, a decrease of 3,903 million yen from the end of the previous consolidated fiscal year. This was mainly due to decreases in long-term borrowings and other current liabilities, among others.
(Net assets)
Total net assets at the end of the current interim consolidated period amounted to 80,225 million yen, an increase of 3,406 million yen from the end of the previous consolidated fiscal year. This was mainly due to an increase in retained earnings resulting from the recording of profit attributable to owners of parent, and an increase in valuation difference on available-for-sale securities.
As a result, the equity ratio increased by 3.0 percentage points from the end of the previous consolidated fiscal year to 65.6%.
Cash Flow Summary
-
Cash flows from operating activities
535 million yen
-
Cash flows from investing activities
(1,252) million yen
-
Cash flows from financing activities
(2,555) million yen
-
Cash and cash equivalents at end of period
6,859 million yen
Overview of Cash Flow Position
decreased 3,266 million yen from the end of the previous consolidated fiscal year to 6,859 million yen.
The status of each type of cash flow during the current interim consolidated period and the factors involved are as follows:
(Cash flows from operating activities)
Net cash provided by operating activities amounted to 535 million yen (compared with 1,105 million yen in the same period last year). This was mainly due to the recording of profit before income taxes as well as depreciation and amortization expenses, despite an increase in accounts receivable and a decrease in accounts payable.
(Cash flows from investing activities)
Net cash used in investing activities was 1,252 million yen (5,959 million yen in the same period last year). This was mainly due to expenditures for the acquisition of shares in subsidiaries and affiliates.
(Cash flows from financing activities)
Net cash used in financing activities was 2,555 million yen (compared with net cash provided of 1,382 million yen in the same period of the previous year). This was mainly due to repayments of long-term and short-term borrowings.